Skip to content

13F-HR filed by Decheng Capital Management III (Cayman), LLC

Decheng Capital Management III (Cayman), LLC filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-09, with 26 holding rows worth $267,206,983.

Accession
0001104659-23-017522
Filed
2023-02-09
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2022

A holdings report, 26 entries on the cover page, a total value of $267,206,983 stated on the cover page (in dollars after the unit check, H1), rows summing to $267,206,983 with VALUE read as dollars as filed, 13F file number 028-22474. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Alabama Power 5.20% Div Qualif010392595PFD6,708,288$49,305,917dollars as filed
ZENTALIS PHARMACEUTICALS INC98943L107COMMON STOCK1,824,583$36,747,102dollars as filed
PROMETHEUS BIOSCIENCES INC74349U108COM250,000$27,500,000dollars as filed
CUE HEALTH INC229790100COM8,980,909$18,590,482dollars as filed
ARCUS BIOSCIENCES INC03969F109COM869,790$17,987,257dollars as filed
ILLUMINA INC452327109COM80,859$16,349,690dollars as filed
ALBIREO PHARMA INC01345P106COMMON STOCK623,342$13,470,421dollars as filed
10X GENOMICS INC CL A COM88025U109Stock359,554$13,102,148dollars as filed
PACIFIC BIOSCIENCES CALIF INC COM69404D108Stock1,463,872$11,974,473dollars as filed
BeyondSpring Inc.00BD36JB9SHS4,958,143$9,321,309dollars as filed
HORIZON THERAPEUTICS PLCG46188101SHS78,900$8,978,820dollars as filed
TERNS PHARMACEUTICALS INC COM880881107Stock714,285$7,271,421dollars as filed
WHITEHAWK THERAPEUTICS INC00032Q104CMN526,329$6,752,801dollars as filed
Mersana Therapeutics Inc59045L106Common Stock904,268$5,299,010dollars as filed
ADICET BIO INC007002108COM580,000$5,185,200dollars as filed
EQUILLIUM INC29446K106COM4,447,308$4,892,039dollars as filed
AURA BIOSCIENCES INC05153U107COMMON STOCK293,333$3,079,997dollars as filed
SEATTLE GENETICS INC812578102COM23,014$2,957,529dollars as filed
ARGENX SE SPONSORED ADR04016X101ADR5,529$2,094,551dollars as filed
AtriCure Inc.004963C20COM46,259$2,052,974dollars as filed
Pyxis Oncology, Inc (formerly Apexigen)03759B102COM1,894,551$1,292,084dollars as filed
SEMA4 HOLDINGS CORP81663L101COM3,418,929$902,597dollars as filed
SCYNEXIS INC811292200COM NEW555,555$866,666dollars as filed
NAUTILUS BIOTECHNOLOGY INC63909J108COM300,000$540,000dollars as filed
OWLET INC69120X107COM898,400$502,295dollars as filed
Ohr Pharmaceutical Inc64132K102COM1,000,000$190,200dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-23-017522this filing2023-02-09acceptance time not in the bulk data set